Chief Financial Officer of Lyell Immunopharma Charles Newton Buys 989% More Shares

Potential Lyell Immunopharma, Inc. (NASDAQ:LYEL) shareholders may wish to note that the Chief Financial Officer, Charles Newton, recently bought US$112k worth of stock, paying US$0.56 for each share. We reckon that's a good sign, especially since the purchase boosted their holding by 989%.

View our latest analysis for Lyell Immunopharma

Lyell Immunopharma Insider Transactions Over The Last Year

Notably, that recent purchase by Charles Newton is the biggest insider purchase of Lyell Immunopharma shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of US$0.58. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. The good news for Lyell Immunopharma share holders is that insiders were buying at near the current price.

In the last twelve months Lyell Immunopharma insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

Insider Ownership Of Lyell Immunopharma

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data suggests Lyell Immunopharma insiders own 3.0% of the company, worth about US$4.3m. I generally like to see higher levels of ownership.

So What Does This Data Suggest About Lyell Immunopharma Insiders?

The recent insider purchases are heartening. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Lyell Immunopharma stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Lyell Immunopharma. For instance, we've identified 4 warning signs for Lyell Immunopharma (1 doesn't sit too well with us) you should be aware of.

Of course Lyell Immunopharma may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.